In person vs. via telemedicine . | n . | Baseline . | Immediately after education* . | 3 months after education† . |
---|---|---|---|---|
HbA1c†, #, ††, ‡‡ (%) | ||||
In person | 18 | 8.6 ± 1.6 | 7.8 ± 1.3 | 7.6 ± 1.3 |
Via telemedicine | 19 | 8.7 ± 2.1 | 7.8 ± 1.6 | 7.8 ± 2.2 |
Total | 37 | 8.6 ± 1.8 | 7.8 ± 1.5 | 7.8 ± 1.8 |
LDL cholesterol§, **, ††, ‡‡ (mmol/l) | ||||
In person | 19 | 2.93 ± 0.74 | 2.79 ± 0.68 | 2.67 ± 0.97 |
Via telemedicine | 15 | 2.84 ± 0.98 | 2.47 ± 0.86 | 2.55 ± 0.97 |
Total | 34 | 2.89 ± 0.84 | 2.65 ± 0.77 | 2.62 ± 0.96 |
PAID scale§, ‖, **, ††, ‡‡ | ||||
In person | 17 | 35.8 ± 23.4 | 33.6 ± 17.0 | 29.4 ± 17.8 |
Via telemedicine | 14 | 37.4 ± 25.8 | 28.1 ± 22.0 | 27.4 ± 17.9 |
Total | 31 | 36.6 ± 24.1 | 31.1 ± 19.2 | 28.6 ± 17.6 |
ADS scale§,**, ††, ‡‡ | ||||
In person | 19 | 20.1 ± 4.7 | 19.3 ± 2.7 | 18.6 ± 4.2 |
Via telemedicine | 15 | 20.1 ± 4.1 | 17.1 ± 3.7 | 18.6 ± 3.5 |
Total | 34 | 20.1 ± 4.4 | 18.3 ± 3.3 | 18.6 ± 3.9 |
Treatment satisfaction‡,**, ††, ‡‡ | ||||
In person | 16 | 23.8 ± 7.9 | 30.7 ± 3.8 | 29.1 ± 5.3 |
Via telemedicine | 12 | 22.8 ± 8.6 | 30.9 ± 4.2 | 31.3 ± 4.2 |
Total | 28 | 23.4 ± 8.1 | 30.8 ± 3.9 | 30.0 ± 5.1 |
DQOL scale‡, **, ††, ‡‡ | ||||
In person | 19 | 61.2 ± 15.0 | 69.6 ± 11.8 | 68.4 ± 13.5 |
Via telemedicine | 16 | 63.4 ± 13.0 | 71.4 ± 12.2 | 69.1 ± 11.0 |
Total | 35 | 62.2 ± 13.9 | 70.4 ± 11.8 | 68.7 ± 12.3 |
In person vs. via telemedicine . | n . | Baseline . | Immediately after education* . | 3 months after education† . |
---|---|---|---|---|
HbA1c†, #, ††, ‡‡ (%) | ||||
In person | 18 | 8.6 ± 1.6 | 7.8 ± 1.3 | 7.6 ± 1.3 |
Via telemedicine | 19 | 8.7 ± 2.1 | 7.8 ± 1.6 | 7.8 ± 2.2 |
Total | 37 | 8.6 ± 1.8 | 7.8 ± 1.5 | 7.8 ± 1.8 |
LDL cholesterol§, **, ††, ‡‡ (mmol/l) | ||||
In person | 19 | 2.93 ± 0.74 | 2.79 ± 0.68 | 2.67 ± 0.97 |
Via telemedicine | 15 | 2.84 ± 0.98 | 2.47 ± 0.86 | 2.55 ± 0.97 |
Total | 34 | 2.89 ± 0.84 | 2.65 ± 0.77 | 2.62 ± 0.96 |
PAID scale§, ‖, **, ††, ‡‡ | ||||
In person | 17 | 35.8 ± 23.4 | 33.6 ± 17.0 | 29.4 ± 17.8 |
Via telemedicine | 14 | 37.4 ± 25.8 | 28.1 ± 22.0 | 27.4 ± 17.9 |
Total | 31 | 36.6 ± 24.1 | 31.1 ± 19.2 | 28.6 ± 17.6 |
ADS scale§,**, ††, ‡‡ | ||||
In person | 19 | 20.1 ± 4.7 | 19.3 ± 2.7 | 18.6 ± 4.2 |
Via telemedicine | 15 | 20.1 ± 4.1 | 17.1 ± 3.7 | 18.6 ± 3.5 |
Total | 34 | 20.1 ± 4.4 | 18.3 ± 3.3 | 18.6 ± 3.9 |
Treatment satisfaction‡,**, ††, ‡‡ | ||||
In person | 16 | 23.8 ± 7.9 | 30.7 ± 3.8 | 29.1 ± 5.3 |
Via telemedicine | 12 | 22.8 ± 8.6 | 30.9 ± 4.2 | 31.3 ± 4.2 |
Total | 28 | 23.4 ± 8.1 | 30.8 ± 3.9 | 30.0 ± 5.1 |
DQOL scale‡, **, ††, ‡‡ | ||||
In person | 19 | 61.2 ± 15.0 | 69.6 ± 11.8 | 68.4 ± 13.5 |
Via telemedicine | 16 | 63.4 ± 13.0 | 71.4 ± 12.2 | 69.1 ± 11.0 |
Total | 35 | 62.2 ± 13.9 | 70.4 ± 11.8 | 68.7 ± 12.3 |
Data are means ± SD. All post-measures for all subjects were not available.
Obtained immediately after visit;
obtained 3 months after third educational visit. Baseline vs. post-education unadjusted for age and BMI:
P < 0.01,
P < 0.05,
NS. Baseline vs. post-education adjusted for age and BMI:
¶ P < 0.05,
P < 0.1,
NS. In person vs. via telemedicine:
NS. Time × condition:
NS.